As I reflect on my decade-long journey covering Inovio Pharmaceuticals, I’m reminded of my most recent piece, “A Pivotal Moment Approaches for Inovio,” published in July 2024. At the time, I assigned a neutral rating to the company, with its stock hovering around $8.98. Since then, I’ve been closely monitoring the biotech firm’s progress, particularly as it prepares to submit its Biologics License Application (BLA).
As a seasoned analyst, I want to emphasize that my opinions are entirely my own and not influenced by any external factors. I do not currently hold a position in Inovio or any other company mentioned in this article, but I may choose to initiate a long position in the coming days. It’s essential to recognize that past performance is not a reliable indicator of future success, and investors should exercise caution when making decisions.
Inovio’s upcoming BLA submission will undoubtedly be a critical milestone, and I’ll be closely watching the developments. As an independent analyst, I strive to provide unbiased insights, and my views may not align with those of Seeking Alpha or other experts. It’s crucial to consult with a licensed financial advisor before making any investment decisions.
Leave a Reply